Phosphorylation of TCTP as a Marker for Polo like Kinase 1 Activity In Vivo英文文献.pdfVIP

ANTICANCER RESEARCH 30: 4973-4986 (2010) Phosphorylation of TCTP as a Marker for Polo-like Kinase-1 Activity In Vivo * ULISSE CUCCHI, LAURA M. GIANELLINI, ANNA DE PONTI , FRANCESCO SOLA, RACHELE ALZANI, VERONICA PATTON, ALICE PEZZONI, SONIA TROIANI, MARIA B. SACCARDO, SIMONA RIZZI, MARIA L. GIORGINI, PAOLO CAPPELLA, ITALO BERIA and BARBARA VALSASINA BU Oncology, Nerviano Medical Sciences s.r.l., 20014, Nerviano, Italy Abstract. Polo-like kinase 1 (PLK1) is the master regulator constitutive expression in NIH3T3 cells induces reduced of mitosis and a target for anticancer therapy. To develop a serum requirements and growth in soft agar. In addition, PLK1 marker of PLK1 activity in cells and tumour tissues, this in vitro transformed cells form tumours after subcutaneous study focused on translational controlled tumour protein injection in athymic nude mice (3). Furthermore, PLK1 (TCTP) and identified serine 46 as a site phosphorylated by depletion (4) or inhibition by small molecules is sufficient to PLK1 in vitro. Using an antibody raised against phospho- drive a mitotic cell-cycle block followed by apoptosis in TCTP-Ser46, it was demonstrated that phosphorylation at tumour cell lines and xenograft models. PLK1 is present in all this site correlates with PLK1 level and kinase activity in proliferating normal tissues, while it is absent in non- cells. Moreover, PLK1 depletion by siRNA or inactivation by proliferating ones. It is overexpressed in different tumour types specific inhibitors cause